一种可注射的脂肪酸共聚物(ARA 3000 BETA),有望用于治疗骨关节炎。
An injectable copolymer of fatty acids (ARA 3000 BETA) as a promising treatment for osteoarthritis.
机构信息
IRMB, University of Montpellier, INSERM, Montpellier, France.
ECELLFRANCE, University of Montpellier, INSERM, CHU Montpellier, Montpellier, France.
出版信息
Sci Rep. 2023 May 13;13(1):7783. doi: 10.1038/s41598-023-34206-8.
Osteoarthritis (OA) is the most prevalent rheumatic disease and a fast growing cause of disability. Current pharmacological treatments include antalgics and non-steroid anti-inflammatory drugs to control pain and inflammation as well as slow acting drugs such as intra-articular (IA) administration of hyaluronic acid. Oral supplementation or diet rich in polyunsaturated free fatty acids are proposed but evidence for benefit is still under debate. We here investigated the therapeutic potential of ARA 3000 BETA, an injectable copolymer of fatty acids, at the structural level in OA. Collagenase-induced osteoarthritis model was induced in C57BL/6 mice by collagenase injection into knee joint. Mice were treated with one or two IA or four intra-muscular injections (IM) of ARA 3000 BETA. At sacrifice, knee joints were recovered for cartilage analysis by confocal laser scanning microscopy (CLSM) and bone analysis by micro-computed tomography system. OA histological scoring was performed after safranin O/fast green staining. Histological analysis revealed a protective effect against cartilage degradation in treated knee joints after IM and IA administration. This was confirmed by CLSM with a significant improvement of all articular cartilage parameters, including thickness, volume and surface degradation whatever the administration route. A slight protective effect was also noticed on subchondral bone parameters and knee joint calcification after IM administration and to a lesser extent, two IA injections. We demonstrated the therapeutic efficacy of injectable ARA 3000 BETA in OA with a protection against cartilage and bone alterations providing the proof-of-concept that clinical translation might be envisioned to delay disease progression.
骨关节炎(OA)是最常见的风湿性疾病,也是导致残疾的主要原因。目前的药物治疗包括镇痛药和非甾体抗炎药,以控制疼痛和炎症,以及具有缓慢作用的药物,如关节内(IA)注射透明质酸。口服补充或富含多不饱和游离脂肪酸的饮食也被提出,但获益的证据仍存在争议。我们在此研究了一种可注射脂肪酸共聚物 ARA 3000 BETA 在 OA 结构水平上的治疗潜力。通过向膝关节注射胶原蛋白酶,在 C57BL/6 小鼠中诱导胶原酶诱导的 OA 模型。用 IA 或 IM 注射 ARA 3000 BETA 对小鼠进行一次或两次治疗。在处死时,通过共聚焦激光扫描显微镜(CLSM)回收膝关节进行软骨分析,并通过微计算机断层扫描系统回收膝关节进行骨骼分析。通过番红 O/快绿染色进行 OA 组织学评分。组织学分析显示,IA 和 IM 给药后,治疗性膝关节对软骨降解具有保护作用。这通过 CLSM 得到了证实,所有关节软骨参数均得到了显著改善,包括厚度、体积和表面降解,无论给药途径如何。在 IM 给药后,对软骨下骨参数和膝关节钙化也有轻微的保护作用,而 IA 注射两次的保护作用较小。我们证明了可注射 ARA 3000 BETA 在 OA 中的治疗效果,对软骨和骨骼改变具有保护作用,为临床转化以延缓疾病进展提供了概念验证。